3-(1-Azabicyclo[3.2.1]octan-5-yl)-4-chloro-1,2,5-thiadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 3-(1-Azabicyclo[3.2.1]octan-5-yl)-4-chloro-1,2,5-thiadiazole
• 化学式: C₉H₁₂ClN₃S
• 分子量: 229.73
• InChiKey: IWUNBZVYYZUQMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  57.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Method for treating anxiety using an azabicyclic oxadiazole or thiadiazole compound
  申请人：ELI LILLY AND COMPANY

  公开号：EP0709093A2

  公开（公告）日：1996-05-01

  The present invention provides the use of a compound wherein X is oxygen or sulphur; R is hydrogen, amino, halogen, -CHO, -NO₂, -OR⁴, -SR⁴, -SOR⁴, -SO₂R⁴, C₃₋₇-cycloalkyl, C₄₋₈-(cycloalkylalkyl), -Z-C₃₋₇-cycloalkyl, and -Z-C₄₋₈-(cycloalkylalkyl) wherein R⁴ is straight or branched C₁₋₁₅-alkyl, straight or branched C₂₋₁₅-alkenyl, straight or branched C₂₋₁₅-alkynyl, each of which is optionally substituted with one or more halogens, -CF₃, -CN, phenyl or phenoxy wherein phenyl or phenoxy is optionally substituted with halogen, -CN, C₁₋₄-alkyl, C₁₋₄-alkoxy, -OCF₃, -CONH₂ or -CSNH₂; or R is phenyl or benzyloxycarbonyl, each of which is optionally substituted with halogen, -CN, C₁₋₄-alkyl, C₁₋₄-alkoxy, -OCF₃, -CONH₂ or -CSNH₂; or R is -OR⁵Y, -SR⁵Y, -OR⁵ZY, -SR⁵ZY, -O-R⁴-Z-R⁵ or -S-R⁴-Z-R⁵ wherein Z is oxygen or sulphur, R5 is straight or branched C₁₋₁₅-alkynyl, and Y is a 5 or 6 membered heterocyclic group containing one to four N, O or S atom(s) or a combination thereof, which heterocyclic group is optionally substituted at carbon or nitrogen atom(s) with straight or branched C₁₋₆-alkyl, phenyl or benzyl, or which heterocyclic group is optionally fused with a phenyl group; and G is selected from one of the following azabicyclic rings wherein the thiadiazole or oxadiazole ring can be attached at any carbon atom of the azabicyclic ring; R¹ and R may be present at any position, including the point of attachment of the thiadiazole or oxadiazole ring, and independently are hydrogen, straight or branched C₁₋₅-alkyl, straight or branched C₂₋₅ alkenyl, straight or branched C₂₋₅-alkynyl, straight or branched C₁₋₁₀-alkoxy, straight or branched C₁₋₅-alkyl substituted with -OH, OR⁴, halogen, -NH₂ or carboxy; R³ is H, straight or branched C₁₋₅-alkyl, straight or branched C₂₋₅-alkenyl or straight or branched C₂₋₅-alkynyl; n is 0, 1 or 2; m is 0, 1 or 2; p is 0, 1 or 2; q is 1 or 2; and --- is a single or double bond; or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of anxiety.

  本发明提供了一种化合物的用途 其中 X 是氧或硫 R 是氢、氨基、卤素、-CHO、-NO₂、-OR⁴、-SR⁴、-SOR⁴、-SO₂R⁴、C₃₋₇-环烷基、C₄₋₈-(环烷基)、-Z-C₃₋₇-环烷基、和 -Z-C₄₋₈-(环烷基)，其中 R⁴ 是直链或支链 C₁₋₁₅-烷基、直链或支链 C₂₋₁₅- 烷基、直链或支链 C₂₋₁₅-炔基，其中每个均任选被一个或多个卤素、-CF₃、-CN、苯基或苯氧基，其中苯基或苯氧基任选被卤素、-CN、C₁₋₄-烷基、C₁₋₄-烷氧基、-OCF₃、-CONH₂或-CSNH₂取代；或 R 是苯基或苄氧羰基，它们各自被卤素、-CN、C₁₋₄-烷基、C₁₋₄-烷氧基、-OCF₃、-CONH₂或-CSNH₂任选取代；或 R 是 -OR⁵Y、-SR⁵Y、-OR⁵ZY、-SR⁵ZY、-O-R⁴-Z-R⁵ 或 -S-R⁴-Z-R⁵，其中 Z 是氧或硫、R5 是直链或支链 C₁₋₁₅-炔基，Y 是含有 1 至 4 个 N、O 或 S 原子的 5 或 6 位杂环基团、O 原子或 S 原子或其组合，该杂环基团可选择在碳原子或氮原子上被直链或支链 C₁₋₆-烷基、苯基或苄基取代，或该杂环基团可选择与苯基融合；G 选自下列偶氮双环之一 其中噻二唑或噁二唑环可连接在氮杂环的任何碳原子上；R¹ 和 R 可存在于任何位置，包括噻二唑或噁二唑环的连接点，且独立地为氢、直链或支链 C₁₋₅ 烷基、直链或支链 C₂₋₅ 烯基、直链或支链 C₂₋₅ 炔基、直链或支链 C₁₋₁₀-烷氧基、被 -OH、OR⁴、卤素、-NH₂ 或羧基取代的直链或支链 C₁₋₅-烷基；R³ 是 H、直链或支链 C₁₋₅-烷基、直链或支链 C₂₋₅-烯基或直链或支链 C₂₋₅-炔基；n 是 0、1 或 2；m 是 0、1 或 2；p 是 0、1 或 2；q 是 1 或 2；以及---是单键或双键；或 其药学上可接受的盐，用于制造治疗焦虑症的药物。
• HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE
  申请人：NOVO NORDISK A/S

  公开号：EP0687266A1

  公开（公告）日：1995-12-20
• ANTIPSYCHOTIC METHOD WITH THIADIAZOLE AND OXADIAZOLE DERIVATIVES
  申请人：NOVO NORDISK A/S

  公开号：EP0714394B1

  公开（公告）日：2001-06-20
• ANTIPSYCHOTIC METHOD
  申请人：NOVO NORDISK A/S

  公开号：EP0714394A1

  公开（公告）日：1996-06-05
• A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS
  申请人：NOVO NORDISK A/S

  公开号：EP0790995A1

  公开（公告）日：1997-08-27